Evidence-based mechanisms · Clinical indications · Dosing protocols · Stack recommendations · 2026 FDA regulatory status
⚖️ April 2026 Regulatory Status: RFK Jr. announced Feb 27, 2026 that ~14 of 19 Category 2 peptides will return to Category 1 (legal for compounding with Rx). No formal FDA Federal Register notice published yet as of April 7, 2026. Each entry shows current status. Expected to remain Category 2: Melanotan II, GHRP-2, GHRP-6, LL-37, PEG-MGF. Semaglutide/tirzepatide compounding: consult current FDA guidance. This tool is for licensed prescribers only.
⌕
loading...
Clinical Reference — Physician Use Only. Evidence ratings (1–10) reflect quality of human data: 1–3 = animal/in vitro only, 4–5 = small human studies or case series, 6–7 = multiple human trials, 8–9 = RCTs/FDA approval, 10 = multiple Phase III RCTs. Evidence quality does not equal clinical utility. Regulatory status reflects April 2026 — pending formal FDA publication. All prescribing requires clinical judgment, informed consent, and appropriate monitoring.